Academic and Government: Waiting on WashingtonThin moat

Thermo Fisher Scientific (TMO) — moat facet

Thermo Fisher's academic and government customers buy on budgets set in Washington and Beijing, and in 2025 both held them back.

Academic and government laboratories buy on budgets set by legislatures, and in 2025 those budgets held them back. The 10-K says "Revenues in the academic and government market declined, driven by customer hesitancy in a more uncertain environment in the U.S. and macro conditions in China"1. On the January call management said the market declined in the low single digits for the full year2.

Revenue by region, second quarter 2026 ($M)6,149North America3,311Europe2,104Asia-Pacific430OtherThermo Fisher Form 10-Q Q2 2026
North America grew slowest of the three large regions.

The company names the mechanism in its risk factors: "Spending by some of these customers fluctuates based on budget allocations and the timely passage of the annual federal budget"3. It also noted that in October 2025 the federal government entered a shutdown4.

Thermo Fisher does not disclose how much revenue comes from this group. Its 2026 guidance assumed conditions similar to 20255.

The relationship recovered a little in 2026: the market grew low single digits in the second quarter6. North America, where federal funding matters most, grew low single digits while Europe and Asia-Pacific grew high single digits7; North American revenue was $6,149 million in the quarter8.

Management's guidance treats the group cautiously. In January the chief executive said the company's assumption for academic and government was "similar conditions to last year in aggregate"9. That is a plan for no recovery, which makes any improvement upside rather than a requirement.

This relationship is thin. It would improve if academic and government growth reached mid-single digits, and worsen if another shutdown or budget cut turned it negative again.

Moat trajectory: Holding steady

Declined low single digits in 2025; grew low single digits in Q2 2026.

The number that tests this moat
Reported
North America revenue, latest quarter
$6,149M (Q2 2026)

Where US funding decisions land; growth below Europe and Asia again would mean federal budgets are still holding labs back.

Source: Thermo Fisher Form 10-Q, Q2 2026 ↗
References
  1. ReportedThe 10-K says "Revenues in the academic and government market declined, driven by customer hesitancy in a more uncertain environment in the U.S. and macro conditions in China".
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - Item 1A risk factors and competition. — FY2025 · publ. 26 February 2026 · source ↗
  2. ReportedOn the January call management said the market declined in the low single digits for the full year.
    Thermo Fisher Scientific fourth-quarter 2025 earnings call transcript (Motley Fool) - initial 2026 guidance, tariffs, academic and government demand, Clario's 2025 revenue and the new CFO. — Q4 2025 · publ. 29 January 2026 · source ↗
  3. ReportedThe company names the mechanism in its risk factors: "Spending by some of these customers fluctuates based on budget allocations and the timely passage of the annual federal budget".
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - Item 1A risk factors and competition. — FY2025 · publ. 26 February 2026 · source ↗
  4. ReportedIt also noted that in October 2025 the federal government entered a shutdown.
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - Item 1A risk factors and competition. — FY2025 · publ. 26 February 2026 · source ↗
  5. ReportedIts 2026 guidance assumed conditions similar to 2025.
    Thermo Fisher Scientific fourth-quarter 2025 earnings call transcript (Motley Fool) - initial 2026 guidance, tariffs, academic and government demand, Clario's 2025 revenue and the new CFO. — Q4 2025 · publ. 29 January 2026 · source ↗
  6. ReportedThe relationship recovered a little in 2026: the market grew low single digits in the second quarter.
    Thermo Fisher Scientific second-quarter 2026 earnings call transcript (Motley Fool) - organic growth by segment and market, China, the raised 2026 guidance, leverage, adjusted ROIC and the microbiology sale. Figures from the transcript body, not the summary block - 2026 guidance, capital deployment, leverage and adjusted ROIC. — Q2 2026 · publ. 23 July 2026 · source ↗
  7. ReportedNorth America, where federal funding matters most, grew low single digits while Europe and Asia-Pacific grew high single digits; North American revenue was $6,149 million in the quarter.
    Thermo Fisher Scientific second-quarter 2026 earnings call transcript (Motley Fool) - organic growth by segment and market, China, the raised 2026 guidance, leverage, adjusted ROIC and the microbiology sale. Figures from the transcript body, not the summary block - organic growth by segment, end market and region, and the microbiology sale. — Q2 2026 · publ. 23 July 2026 · source ↗
  8. ReportedNorth America, where federal funding matters most, grew low single digits while Europe and Asia-Pacific grew high single digits; North American revenue was $6,149 million in the quarter.
    Thermo Fisher Scientific Form 10-Q for the quarter ended 27 June 2026 - revenue by business and by type, the Clario purchase price, the microbiology sale, share repurchases, dividends and the balance sheet. — Q2 2026 · publ. 31 July 2026 · source ↗
  9. ReportedIn January the chief executive said the company's assumption for academic and government was "similar conditions to last year in aggregate".
    Thermo Fisher Scientific fourth-quarter 2025 earnings call transcript (Motley Fool) - initial 2026 guidance, tariffs, academic and government demand, Clario's 2025 revenue and the new CFO. — Q4 2025 · publ. 29 January 2026 · source ↗
Sources
Generated September 28, 2026